Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer.

Cancer research - 1 Feb 2025

Wang Simeng, Lai Jia-Cheng, Li Yu, Tang Chengfang, Lu Jiajia, Han Min, Ye Xianjiang, Jia Lina, Cui Wei, Yang Jingyu, Wu Chunfu, Wang Lihui

Abstract excerpt

Mutant EGFR is a common driver of non-small cell lung cancer (NSCLC). Although mutant EGFR has been reported to limit the efficacy of immunotherapy, a subset of patients with EGFR-mutant NSCLC benefit from treatment with immune checkpoint inhibitors. A better understanding of how co-occurring genomic alterations in oncogenic driver genes impact immunotherapy efficacy may provide a more complete understanding of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cyclin-Dependent Kinase Inhibitor p16

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Lung Neoplasms

Share to Tumor Microenvironment

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 39514336
DOI: 10.1158/0008-5472.CAN-24-1817

Genes

EGFR
CDKN2A
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer.PMID 39514336Read ↗

Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer.Semantic proximity Read ↗

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.Semantic proximity Read ↗

Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancerSemantic proximity Read ↗

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.Semantic proximity Read ↗

Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.Semantic proximity Read ↗

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progressionSemantic proximity Read ↗

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomasSemantic proximity Read ↗

Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2Semantic proximity Read ↗

Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistanceSemantic proximity Read ↗

KRAS mutation promotes immune escape of lung adenocarcinoma via ZNF24/SLC7A5/PD-L1 axisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.